These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16894087)

  • 41. Unsuspected exposure to cocaine in preschool children from a Mediterranean city detected by hair analysis.
    Joya X; Papaseit E; Civit E; Pellegrini M; Vall O; Garcia-Algar O; Scaravelli G; Pichini S
    Ther Drug Monit; 2009 Jun; 31(3):391-5. PubMed ID: 19333147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adolescent substance use and abuse: recognition and management.
    Griswold KS; Aronoff H; Kernan JB; Kahn LS
    Am Fam Physician; 2008 Feb; 77(3):331-6. PubMed ID: 18297958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Current approaches to analysis of narcotic drugs in biological substances].
    Kovalenko AE; Kardonskiĭ DA; Eganov AA; Grishin DA; Salomatin EM
    Sud Med Ekspert; 2007; 50(2):28-32. PubMed ID: 17520904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Refusal of urinary or salivary drug screening at school: the position of the SSAM (Swiss Society of Addiction Medicine)].
    Comité de la Société suisse de médecine de I'addiction
    Rev Med Suisse; 2008 May; 4(156):1172-4. PubMed ID: 18630173
    [No Abstract]   [Full Text] [Related]  

  • 45. The current status of drug testing in the U.S. workforce.
    Wong R
    Am Clin Lab; 2002 Apr; 21(3):14-7. PubMed ID: 12038079
    [No Abstract]   [Full Text] [Related]  

  • 46. Trauma, dissociation, and substance dependence in an adolescent male.
    Jaffee WB; Chu JA; Woody GE
    Harv Rev Psychiatry; 2009; 17(1):60-7. PubMed ID: 19205967
    [No Abstract]   [Full Text] [Related]  

  • 47. Development and validation of the Cozart DDS oral fluid collection device.
    Speedy T; Baldwin D; Jowett G; Gallina M; Jehanli A
    Forensic Sci Int; 2007 Aug; 170(2-3):117-20. PubMed ID: 17624706
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An estimate of the proportion of drug-facilitation of sexual assault in four U.S. localities.
    Juhascik MP; Negrusz A; Faugno D; Ledray L; Greene P; Lindner A; Haner B; Gaensslen RE
    J Forensic Sci; 2007 Nov; 52(6):1396-400. PubMed ID: 18093069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [On-site testing for drug abuse in urine].
    Espnes KA; Spigset O; Delaveris GJ; Mørland J; Smith-Kielland A
    Tidsskr Nor Laegeforen; 2006 Sep; 126(17):2257-60. PubMed ID: 16967064
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.
    Clemens KJ; McGregor IS; Hunt GE; Cornish JL
    Drug Alcohol Rev; 2007 Jan; 26(1):9-15. PubMed ID: 17364831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a qualitative liquid chromatography/tandem mass spectrometric method for the detection of narcotics in urine relevant to doping analysis.
    Deventer K; Pozo OJ; Van Eenoo P; Delbeke FT
    Rapid Commun Mass Spectrom; 2007; 21(18):3015-23. PubMed ID: 17708509
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Doping: a paradigm shift has taken place in testing.
    Sottas PE; Saudan C; Saugy M
    Nature; 2008 Sep; 455(7210):166. PubMed ID: 18784700
    [No Abstract]   [Full Text] [Related]  

  • 53. Pressure-assisted capillary electrochromatography with electrospray ionization-mass spectrometry based on silica-based monolithic column for rapid analysis of narcotics.
    Lu M; Zhang L; Feng Q; Xia S; Chi Y; Tong P; Chen G
    Electrophoresis; 2008 Feb; 29(4):936-43. PubMed ID: 18213603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cut-off and toxicity levels for drugs-of-abuse testing.
    MLO Med Lab Obs; 1999 Jul; Suppl():14-5. PubMed ID: 10539653
    [No Abstract]   [Full Text] [Related]  

  • 55. A validated SPME-GC-MS method for simultaneous quantification of club drugs in human urine.
    Brown SD; Rhodes DJ; Pritchard BJ
    Forensic Sci Int; 2007 Sep; 171(2-3):142-50. PubMed ID: 17158009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fatality due to the use of a designer drug MDMA (Ecstasy).
    Kłys M; Rojek S; Woźniak K; Rzepecka-Woźniak E
    Leg Med (Tokyo); 2007 Jul; 9(4):185-91. PubMed ID: 17320458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polysubstance use and its correlates in adolescent ecstasy users in Taiwan.
    Yen CF; Hsu SY; Cheng CP
    Addict Behav; 2007 Oct; 32(10):2286-91. PubMed ID: 17314013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers.
    Pichini S; Pujadas M; Marchei E; Pellegrini M; Fiz J; Pacifici R; Zuccaro P; Farré M; de la Torre R
    J Pharm Biomed Anal; 2008 Jun; 47(2):335-42. PubMed ID: 18262381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of three commercial tests for buprenorphine screening in urine.
    Leino A; Loo BM
    Ann Clin Biochem; 2007 Nov; 44(Pt 6):563-5. PubMed ID: 17961313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does subtle screening for substance abuse work? A review of the Substance Abuse Subtle Screening Inventory (SASSI).
    Feldstein SW; Miller WR
    Addiction; 2007 Jan; 102(1):41-50. PubMed ID: 17207122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.